Back to top
more

Concentra Group Holdings Parent, Inc. (CON)

(Delayed Data from NYSE)

$19.82 USD

19.82
627,711

+0.02 (0.10%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $19.80 -0.02 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Concentra Group (CON) Q2 Earnings Expected to Decline

by Zacks Equity Research

Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Concentra (CON) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Concentra (CON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts Believe Concentra (CON) Could Rally 27.1%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Concentra (CON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Concentra (CON) Upgraded to Buy: Here's Why

by Zacks Equity Research

Concentra (CON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

by Zacks Equity Research

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Does Concentra (CON) Have the Potential to Rally 30.84% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Concentra (CON) points to a 30.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Concentra Group (CON) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Concentra (CON) delivered earnings and revenue surprises of 3.23% and 0.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agilon Health (AGL) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of 100% and 1.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations

by Zacks Equity Research

CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.

Zacks Equity Research

Is Concentra Group Holdings Parent, Inc. (CON) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Concentra Group (CON) and Fresenius (FMS) have performed compared to their sector so far this year.

Zacks Equity Research

Concentra (CON) Upgraded to Buy: Here's Why

by Zacks Equity Research

Concentra (CON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Concentra (CON) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Concentra (CON) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

CVS Health (CVS) Surges 5.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

CVS Health (CVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Best Momentum Stock to Buy for March 21st

by Zacks Equity Research

RWEOY, ASLE and CON made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 21, 2025.

Zacks Equity Research

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

Down -8.49% in 4 Weeks, Here's Why Concentra (CON) Looks Ripe for a Turnaround

by Zacks Equity Research

Concentra (CON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Has Concentra Group Holdings Parent, Inc. (CON) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Concentra Group (CON) and Cencora (COR) have performed compared to their sector so far this year.